The Asia Pacific biologics contract manufacturing market is entering a high-growth phase, supported by rising biopharmaceutical demand, expanding biologics pipelines, and increasing outsourcing among small and virtual biotechnology companies. According to Transparency Market Research, the market is projected to reach US$9.8 billion by 2031, expanding at a 14.5% CAGR from 2021 to 2031. Growing demand for monoclonal antibodies, vaccines, hormones, fusion proteins, and other biologic therapies is encouraging pharmaceutical and biotechnology companies to partner with contract manufacturing organizations (CMOs) to expand production capacity and accelerate commercialization.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=83494

The COVID-19 pandemic further highlighted the strategic importance of biologics manufacturing infrastructure. Rising vaccine requirements drove increased sales of bioreactors, while manufacturers expanded facilities to support vaccine development and production. Government investments, tax incentives, and initiatives aimed at strengthening local biotechnology capabilities are also creating new revenue opportunities across Asia Pacific.

Market Size and Growth

The market's expansion is being driven by the growing adoption of outsourced biopharmaceutical manufacturing in countries such as China and India. Lower manufacturing and operating costs, comparatively affordable labor, favorable investment policies, and expanding pharmaceutical ecosystems are positioning Asia Pacific as an attractive outsourcing destination. In addition, increasing demand for biologics in oncology, autoimmune disorders, and infectious diseases is creating sustained manufacturing requirements.

The vaccines segment is expected to benefit from continued concerns surrounding infectious diseases and future pandemics. At the same time, the expiration of patents covering several biologic medicines is opening opportunities for biosimilar development and cost-efficient manufacturing.

Market Segmentation

By type, monoclonal antibodies accounted for a major share of the market in 2020, supported by their expanding use in oncology and autoimmune disease treatment. Vaccines represent another important growth area, particularly as governments and healthcare organizations strengthen immunization programs.

The market is also benefiting from advances in process intensification (PI), which enables manufacturers to improve productivity, increase production capacity, shorten development timelines, and potentially reduce manufacturing footprints. Optimized digital manufacturing and automation are further helping contract manufacturers improve operational efficiency, quality control, compliance, and responsiveness to changing demand.

Regional Analysis

The Rest of Asia Pacific represented 41.7% of the market in 2020 and is projected to remain highly attractive, with China playing a significant role. China and India are strengthening their positions as biologics manufacturing hubs through expanding infrastructure, skilled workforce availability, and supportive regulatory environments.

Regulatory changes in China allowing pharmaceutical companies to outsource manufacturing to CMOs are also enabling biotechnology companies to focus more heavily on drug discovery and innovation. Meanwhile, Asian manufacturers are increasingly targeting Western markets with biosimilars by leveraging comparatively lower development and manufacturing costs.

Competitive Landscape

The competitive environment includes major companies such as Lonza Group, Samsung Biologics Co., Ltd., Patheon by Thermo Fisher Scientific, Inc., Cambrex Corporation, and Siegfried Holding AG. Market participants are investing in advanced manufacturing infrastructure, process optimization, automation, and cost-efficient production solutions to strengthen their capabilities and meet growing demand from biopharmaceutical companies.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453